Pfizer (PFE) Receives a Hold from Barclays

By Austin Angelo

Barclays analyst Geoff Meacham maintained a Hold rating on Pfizer (PFEResearch Report) yesterday and set a price target of $41. The company’s shares opened today at $40.30.

According to TipRanks.com, Meacham is a 4-star analyst with an average return of 5.3% and a 56.5% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, DBV Technologies SA – American, and Bausch Health Companies Inc.

Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $46, representing a 14.1% upside. In a report issued on April 30, J.P. Morgan also maintained a Hold rating on the stock with a $46 price target.

See today’s analyst top recommended stocks >>

Pfizer’s market cap is currently $234.1B and has a P/E ratio of 21. The company has a Price to Book ratio of 3.69.

Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.